Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis

Background and aimsSera from cancer patients contain tumor-specific autoantibodies directly against antigenic proteins. The identification of tumor autoantigens may have utility in cancer diagnosis, prognosis, and therapy. In this study, we used immunoproteomics analysis to identify tumor proteins that elicit humoral response in colorectal cancer (CRC).Materials and methodsThe CRC cell line HCT116 was used as a source of proteins for two-dimensional polyacrylamide gel electrophoresis and subsequent Western blot analysis in which individual serum from patients with CRC was analyzed for autoantibodies. Proteins that specifically react with sera from cancer patients were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis. In addition, the selected protein expression in tumor tissues collected from 40 patients with CRC were assessed by immunohistochemistry.ResultsAn autoantibody against inosine monophosphate dehydrogenase II (IMPDH2) identified by mass spectrometry was detected in eight out of 25 patients with CRC. However, none of the 15 healthy controls demonstrated autoantibody to IMPDH2.The expression of IMPDH2 in tumor tissue was significantly higher in patients with CRC than that in healthy subjects.ConclusionsThe result confirmed that the immunoproteomics analysis holds considerable promise for the discovery of tumor-associated antigens. IMPDH2 may be a protein biomarker and novel therapeutic target in CRC.

[1]  R. Jackson,et al.  IMP dehydrogenase, an enzyme linked with proliferation and malignancy , 1975, Nature.

[2]  S. Hanash,et al.  Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. , 2001, Cancer research.

[3]  David E. Misek,et al.  Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  R. D. De Abreu,et al.  Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: Enzymological and clinical aspects , 2006, Pediatric blood & cancer.

[5]  S. Katsaragakis,et al.  Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer , 2000, American Journal of Gastroenterology.

[6]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[7]  B. Seliger,et al.  Design of proteome‐based studies in combination with serology for the identification of biomarkers and novel targets , 2002, Proteomics.

[8]  B. Mack,et al.  Allogenic antibody-mediated identification of head and neck cancer antigens. , 2004, Biochemical and biophysical research communications.

[9]  Y. Natsumeda,et al.  Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). , 1994, Life sciences.

[10]  S M Hanash,et al.  An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  David E. Misek,et al.  An Autoantibody-Mediated Immune Response to Calreticulin Isoforms in Pancreatic Cancer , 2004, Cancer Research.

[12]  Laura Beretta,et al.  A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis* , 2002, Molecular & Cellular Proteomics.

[13]  K. Zatloukal,et al.  Identification of tumor antigens in renal cell carcinoma by serological proteome analysis , 2001, Proteomics.

[14]  Liqiang Chen,et al.  Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. , 2007, Current opinion in drug discovery & development.

[15]  Shaji K. Kumar,et al.  Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway , 2005, Oncogene.

[16]  P Ferrara,et al.  In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. , 1992, Analytical biochemistry.

[17]  Jennifer E Van Eyk,et al.  A proteomic primer for the clinician. , 2007, Proceedings of the American Thoracic Society.

[18]  Rosamonde E Banks,et al.  Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma , 2003, Proteomics.

[19]  F. Collart,et al.  Increased inosine-5'-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. , 1992, Cancer research.

[20]  B. Seliger,et al.  Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. , 2003, Biochimica et biophysica acta.

[21]  Neeta Singh,et al.  Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells. , 2004, Life sciences.

[22]  K. Umezawa,et al.  Induction by the guanosine analogue oxanosine of reversion toward the normal phenotype of K-ras-transformed rat kidney cells. , 1989, Cancer research.

[23]  Jan Fagerberg,et al.  Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma , 1999, Cancer Immunology, Immunotherapy.

[24]  B. Mitchell,et al.  Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. , 1995, Biochemical pharmacology.

[25]  T. Takubo,et al.  Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. , 2008, Cancer letters.

[26]  T. Thompson,et al.  Antiproliferative effects of AVN944, a novel inosine 5‐monophosphate dehydrogenase inhibitor, in prostate cancer cells , 2008, International journal of cancer.

[27]  A. Shimizu,et al.  Proteomics-Based Approach Identifying Autoantibody against Peroxiredoxin VI as a Novel Serum Marker in Esophageal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[28]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[29]  S. Hanash,et al.  Proteomics Approaches to Identify Tumor Antigen Directed Autoantibodies as Cancer Biomarkers , 2004, Disease markers.

[30]  D. Schadendorf,et al.  Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. , 2004, Cancer letters.

[31]  S. Hanash.  Disease proteomics : Proteomics , 2003 .

[32]  B. Mitchell,et al.  Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. , 1996, Advances in enzyme regulation.

[33]  S. Hanash,et al.  Disease proteomics , 2003, Nature.

[34]  M. Eisenstein,et al.  CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma , 1997, Nature.

[35]  B. Ye,et al.  Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients , 2008, Clinical Cancer Research.

[36]  G. Omenn.  Strategies for plasma proteomic profiling of cancers , 2006, Proteomics.

[37]  F. Chan,et al.  Asia Pacific consensus recommendations for colorectal cancer screening , 2008, Gut.

[38]  H. Jayaram,et al.  Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. , 2000, Anticancer research.